propiram

Propiram (Algeril, Dirame, Bay 4503) is a partial μ-opioid receptor agonist and weak μ antagonist analgesic from the ampromide family of drugs related to other drugs such as phenampromide and diampromide. It was invented in 1963 in the United Kingdom by Bayer but was not widely marketed, although it saw some limited clinical use, especially in dentistry. Propiram reached Phase III clinical trials in the United States and Canada.

In the Vinony graph

Within Vinony's link graph, propiram is referenced by 824 other articles, and connects out to (+)-catechin, butorphanol and OPRK1.

It sits within the topics 1-Piperidinyl compounds, 2-Pyridyl compounds and Chemical pages without DrugBank identifier.

Its subject is documented across 8 Wikipedia language editions.

Chemical data

Formula: C16H25N3O
Molecular weight: 275.39 g/mol
IUPAC name: N-(1-piperidin-1-ylpropan-2-yl)-N-pyridin-2-ylpropanamide
SMILES: CCC(=O)N(C1=CC=CC=N1)C(C)CN2CCCCC2
InChIKey: ZBAFFZBKCMWUHM-UHFFFAOYSA-N
XLogP: 2.3
Polar surface area: 36.4 Å²
H-bond donors: 0
H-bond acceptors: 3
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Phase 2
Molecule type: Small molecule

via ChEMBL · EBI

Wikidata facts

Subclass of: chemical compound
Mass: 275.2

Show 4 more facts

chemical formula: C₁₆H₂₅N₃O
canonical SMILES: CCC(=O)N(C1=CC=CC=N1)C(C)CN2CCCCC2
MCN code: 2933.33.92
Commons category: Propiram

Sources (2)

via Wikidata · CC0

~2 min read

Encyclopedic overview

4 sections

Contents

Pharmacology
Derivatives
Regulation
References

==Pharmacology== Propiram exhibits weak opioid antagonist activity on the μ receptor—quite a bit weaker than its agonist effects—and the effect on κ- and δ-opioid, σ-receptors, or the NMDA system are not well understood. Other drugs of the partial μ-opioid agonist/antagonist type include meptazinol, buprenorphine, butorphanol, phenazocine, nalbuphine, pentazocine, dezocine and its relatives.

Excerpted from Wikipedia’s “propiram” article, available under the CC BY-SA 4.0 licence.